BioSpace News Archive

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced that stockholders have approved the two proposals voted on at the Company’s Special Meeting of Stockholders held on December 8, 2021.

According to Emergen Research, the global health data archiving market size was USD 3.21 billion in 2020 and is expected to reach USD 9.28 billion in 2028 and register a revenue CAGR of 14.1% during the forecast period, 2021-2028.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that the National Medical Products Administration (NMPA) of China has granted approval of the company’s monoclonal neutralizing antibody (mAb) therapy.

The global Microscope Software Market is expected to be valued at USD 1,490.0 Million by 2028 from USD 568.51 Million in 2020, registering a CAGR of 12.8% through the forecast period.

The New England Journal of Medicine has published positive results from a pivotal Dupixent® clinical trial in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced the closing of the previously announced private investment in public equity financing.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Cardiovascular and Renal Drugs Advisory Committee (“Committee”) meeting on bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.

AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.

Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share.

Takeda Pharmaceutical Company today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY were published in the journal of Clinical Infectious Diseases (CID).